IMpower133: Primry PFS, OS, nd sfety in Ph1/3 study of 1L tezolizumb + crbopltin + etoposide in extensive-stge SCLC S. V. Liu, 1 A. S. Mnsfield, 2 A. Szczesn, 3 L. Hvel, 4 M. Krzkowski, 5 M. J. Hochmir, 6 F. Huemer, 7 G. Losonczy, 8 M. L. Johnson, 9 M. Nishio, 10 M. Reck, 11 T. Mok, 12 S. Lm, 13 D. S. Shmes, 13 J. Liu, 14 B. Ding, 13 F. Kbbinvr, 13 W. Lin, 13 A. Sndler, 13 L. Horn 15 1 Georgetown University, Wshington DC, USA; 2 Myo Clinic, Rochester, MN, USA; 3 Mzowieckie Centrum Leczeni Chorób Płuc i Gruźlicy, Otwock, Polnd; 4 Thomyerov Nemocnice, Pneumologická Klinik 1.LF UK, Prgue, Czech Republic; 5 Centrum Onkologii-Instytut im. M. Skłodowskiej-Curie w Wrszwie, Wrsw, Polnd; 6 Deprtment of Respirtory nd Criticl Cre Medicine & Ludwig Boltzmnn Institute for COPD & Respirtory Epidemiology Bumgrtner Höhe, Otto-Wgner-Spitl, Vienn, Austri; 7 2 nd Deprtment of Respirtory nd Criticl Cre Medicine & Ludwig Boltzmnn Institute for COPD & Respirtory Epidemiology Bumgrtner Höhe, Otto-Wgner-Spitl, Vienn, Austri; 8 Semmelweis Egyetem ÁOK, Pulmonológii Klinik, Budpest, Hungry; 9 Srh Cnnon Reserch Institute/Tennessee Oncology PLLC, Nshville, TN, USA; 10 The Cncer Institute Hospitl, Jpnese Foundtion for Cncer Reserch, Tokyo, Jpn; 11 LungClinic Grosshnsdorf, Airwy Reserch Center North (ARCN), Germn Center for Lung Reserch, Grosshnsdorf, Germny; 12 Stte Key Lbortory of South Chin, The Chinese University of Hong Kong, Hong Kong, Chin; 13 Genentech, Inc., South Sn Frncisco, CA, USA; 14 F. Hoffmnn-L Roche, Ltd., Shnghi, Chin; 15 Vnderbilt University Medicl Center, Nshville, TN, USA Downlod from http://bit.ly/2cvy9it, IMpower133
IMpower133: Globl Phse 1/3, double-blind, rndomized, plcebo-controlled tril evluted tezolizumb + crbopltin + etoposide in 1L ES-SCLC Only ptients with treted brin metstses were eligible. ECOG PS, Estern Coopertive Oncology Group Performnce Sttus; IV, intrvenous; PCI, prophylctic crnil irrdition; PD, progressive disese; PFS, progression-free survivl; R, rndomized; RECIST, Response Evlution Criteri In Solid Tumors. Downlod from http://bit.ly/2cvy9it, IMpower133, Presented by Stephen V. Liu
Overll survivl Clinicl dt cutoff dte: April 24, 2018, 11 months fter the lst ptient ws enrolled. CI, confidence intervl; HR, hzrd rtio; CP/ET, crbopltin + etoposide. Downlod from http://bit.ly/2cvy9it, IMpower133, Presented by Stephen V. Liu
Investigtor-ssessed progression-free survivl Clinicl dt cutoff dte: April 24, 2018, 11 months fter the lst ptient ws enrolled. CI, confidence intervl; HR, hzrd rtio; CP/ET, crbopltin + etoposide. Downlod from http://bit.ly/2cvy9it, IMpower133, Presented by Stephen V. Liu
Confirmed objective response nd durtion of response Censored. b At clinicl cutoff dte: April 24, 2018. CR, complete response; EFS, event-free survivl; PD, progressive disese; PR, prtil response; SD, stble disese. Downlod from http://bit.ly/2cvy9it, IMpower133, Presented by Stephen V. Liu
Summry IMpower133 is the first study in over 20 yers to show cliniclly meningful improvement in OS over the current stndrd-of-cre in 1L ES-SCLC The ddition of tezolizumb to crbopltin nd etoposide provided significnt improvement in OS nd PFS, compred with crbopltin nd etoposide lone in 1L ES-SCLC mos: 12.3 vs. 10.3 months; HR: 0.70 (p = 0.0069); 12-month OS: 51.7% vs. 38.2% mpfs: 5.2 vs. 4.3 months; HR: 0.77 (p = 0.017); 12-month PFS: 12.6% vs. 5.4% The sfety profile of tezolizumb plus crbopltin nd etoposide ws s expected with no new findings Rtes of hemtologic side effects were similr between tretment groups Administrtion of tezolizumb did not compromise the bility to deliver stndrd crbopltin plus etoposide The incidence nd types of immune-relted AEs were similr to those seen with tezolizumb monotherpy 1 3 These dt suggest tht tezolizumb plus crbopltin nd etoposide is new stndrd of cre for the first-line tretment of ES-SCLC 1. Rittmeyer A, et l. Lncet, 2017. 2. Cortinovis D, et l. Ann Oncol, 2017 (Suppl. 5). 3. Fehrenbcher L, et l. Lncet, 2016. Downlod from http://bit.ly/2cvy9it, IMpower133, Presented by Stephen V. Liu